Barely Significant
← all excerpts

Development of an Influenza/COVID-19 Combination mRNA Vaccine Containing a Novel Multivalent Antigen Design That Enhances Immunogenicity of Influenza Virus B Hemagglutinins.

Vaccines (Basel) · 2025 · PMC12197711 · PMID 40573959

1
hedged sentence
closest p
boldest claim

The sentences

The mRNA vaccine candidates with the extended Gly-rich flexible linkers had improved HAI GMTs for both antigens in the B Y A H1 dumbbell compared with their short linker counterparts, although the titer differences did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.